Who Owns COVID-19 Vaccine Patents? The Answer Is Three Different Lists
A worked example from a ForIntel Research Field Atlas. The organizations that publish the COVID-19 vaccines-and-variants field, the ones that hold its patent IP, and the ones that sell the vaccines are three separate lists — and mistaking one for another is the most common error in field diligence.
Ask who owns the intellectual property behind the COVID-19 vaccines and most people will name two companies: Moderna and BioNTech. It is a reasonable guess. They are the household names, their mRNA products defined the pandemic response, and their commercial success is a matter of record.
It is also wrong — or at least, it answers a different question than the one most people think they are asking. When we mapped the COVID-19 vaccines-and-variants research field for a sample Research Field Atlas, the single most useful thing the map produced was not a ranking. It was a separation. The field has three distinct actor lists, and they barely overlap:
- Who publishes the field — a compact, UK-led academic core.
- Who holds the patent IP — academic and state research bodies, heavily Chinese.
- Who sells the vaccines — the Western commercial makers everyone can name.
Read the wrong list for your purpose and you will scout the wrong institutions, approach the wrong partners, or clear the wrong names in a freedom-to-operate check. This piece is about why the three lists diverge, and which one to read for which decision.
The publication map: a UK-led academic core
Aggregate the field's scholarly output by the institution that produced it and a tight leadership set emerges. The University of Oxford leads on field output (49 works in our capped corpus), followed by University College London (31), the University of Hong Kong (29), and then Cambridge, Harvard and Imperial College London (22 each), with the London School of Hygiene & Tropical Medicine close behind (21). The Chinese Academy of Sciences carries an outsized citation footprint relative to its work count, driven by the foundational early-2020 virology papers.
This is the map you want if your question is where is the talent, and whose work is the field built on. A funder deciding where to seed a program, or a department head deciding where to recruit, should start here. The field's most-cited foundational works — the early clinical-characterization papers, the novel-coronavirus and cell-entry virology, the pivotal vaccine-efficacy trials — descend largely from this academic core.
But notice what this map does not tell you: who can stop you from commercializing something. Publication leadership and patent ownership are different games, played by different players.
The patent map: state and academic research bodies, heavily Chinese
Now count the same field by protected invention instead of publication. Read at full strength — full-text and classification, every distinct invention counted once worldwide, assignee names harmonized — the field has translated into roughly 9,250 distinct patent families, 43% of them filed since 2022. It is a large, active IP base.
And the holders are not who the publication map, or the evening news, would lead you to expect:
| Patent holder | Distinct families | Type |
|---|---|---|
| PLA Academy of Military Medical Sciences (China) | 84 | State research |
| University of California | 70 | Academic |
| Tsinghua University | 63 | Academic |
| INSERM (France) | 58 | State research |
| CNRS · Fudan · Chinese Academy of Sciences · Institut Pasteur · CSIC · NIH | ~40–50 each | Academic / state research |
The only company to appear anywhere in the top 25 is Celltrion. Moderna and BioNTech — the two names most people offer when asked who owns COVID vaccine IP — are not in it. They lead only when you narrow the lens to vaccine-specific patents, and even there the University of California still ranks first.
This is the map you want if your question is who holds the defensible invention — for licensing, partnership scouting, competitive positioning, or a freedom-to-operate clearance. It is emphatically not the brand-name vaccine list, and it is not the publication list either.
One honest caveat travels with this map, and it matters: these are counts of patenting activity, not IP value. Academic and state bodies file many narrow families across a whole research space. A commercial maker's handful of foundational families — an mRNA-platform patent, say — can be worth more than dozens of narrow ones. So read the ranking as "who is most active in patenting the field," not "who owns the most commercially valuable estate." Turning filing volume into a value-weighted map (forward citations, claim breadth, family size) is a separate, deeper pass.
The market map: the names you already know
The third list is the one that needed no research: Moderna, BioNTech, and the other commercial makers who brought products to market. It is the most visible map and the least useful for diligence, precisely because it is already public. If your decision depends on who sells the vaccine, you did not need a field atlas. If it depends on who could block a product or license a platform, the market map is a trap — it points you at two companies and hides the state research apparatus that actually holds most of the field's protected inventions.
The measurement lesson: how you count decides who wins
Here is the part worth sitting with, because it generalizes far beyond COVID. Our own read of this field flipped once during analysis.
An early, quicker patent pass — title-only, single-jurisdiction — ranked the field as commercial-vaccine-maker-led, matching the intuitive answer. It was wrong, and it was wrong for a mechanical reason: counting raw US titles double-counts the same invention filed in multiple countries and over-weights whoever names their filings with obvious molecule terms. The gold-standard read — family-deduplicated across the US, Europe and the PCT, full-text plus classification, assignee names harmonized — corrected the ranking to academic-and-state-led.
The lesson is not "patents are hard." It is that the counting method is load-bearing. A field map is only as trustworthy as the deduplication behind it. When someone hands you a patent ranking, the first question is not "who's on top" — it is "families or filings, and deduplicated across which jurisdictions." Get that wrong and you will confidently read the field backwards.
What to do with three maps instead of one
The practical discipline is simple once the separation is visible:
- Scouting talent or seeding research? Read the publication map. Start with the UK-led academic core and the institutions carrying the highest citation footprint per work — they sit closest to the field's founding layer.
- Licensing, partnership, or freedom-to-operate? Read the patent map, family-deduplicated and global. The household-name vaccine companies are not your main counterparties here; the state and academic research bodies are.
- Sizing the commercial market? The market map is already public — but do not let it stand in for the other two.
The single most consequential read from this field: a state research apparatus — China's, plus the European state bodies — holds more of the COVID-19 field's protected IP than the companies whose vaccines you took. That is not a claim about vaccines, science, or merit. It is a claim about structure, and structure is exactly what gets missed when a field is read through the one map that happened to make the news.
See the full field map
The worked example above is drawn from a public sample of a ForIntel Research Field Atlas, which maps a field across five vectors — concept-cluster structure, citation magnitude, institutional concentration, time evolution, and IP translation. Every count traces to a retrieved record, capped pulls are reported as floors, and the patent read is gold-standard. It maps field structure, not scientific merit.
- Read the sample: ForIntel Research Field Atlas — COVID-19 vaccines and variants
- Commission one for your field: reach the ForIntel desk at forintel@foragentis.com.
